Could a common drug boost brain blood flow and fight Alzheimer's?
NCT ID NCT05386914
First seen Mar 17, 2026 · Last updated Jun 23, 2026 · Updated 18 times
Summary
This early-stage study tests whether sirolimus, an FDA-approved drug, can improve blood flow to the brain in healthy adults aged 45-65. Some participants carry a gene (APOE4) that raises Alzheimer's risk, while others do not. The goal is to see if the drug affects brain blood flow differently based on genetics, and to explore links between lung and brain blood flow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Missouri-Columbia
Columbia, Missouri, 65212, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sirolimus
What this could lead to
If it works, this could point toward a way to improve brain blood flow and potentially delay Alzheimer's in people with a genetic risk.
What could go wrong
This is a very early phase 1 study in healthy volunteers, not patients. It only looks at short-term blood flow changes, not whether it prevents or treats Alzheimer's.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.